ERBB2 and triple-negative breast carcinoma: Since select HR-HER2+ tumors may not respond well to anti-HER2 therapies, these tumors biologically may behave like triple negative breast cancers, thus resulting in a lower likelihood of pCR following neoadjuvant chemotherapy [15,23].